A Study to Evaluate the Efficacy and Safety of BMN 111 in Children With Achondroplasia
Conditions
Achondroplasia
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
Children's Hospital & Research Center Oakland, Oakland, California, United States
Harbor - UCLA Medical Center, Torrance, California, United States
Alfred I. duPont Hospital for Children, Wilmington, Delaware, United States
Emory University, Decatur, Georgia, United States
Ann and Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, United States
Johns Hopkins University, Baltimore, Maryland, United States
University of Missouri, Columbia, Missouri, United States
Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
Baylor College of Medicine, Houston, Texas, United States
Seattle Children's Hospital, Seattle, Washington, United States
Medical College of Wisconsin, Children's Hospital, Milwaukee, Wisconsin, United States
The Children's Hospital at Westmead, Westmead, New South Wales, Australia
Murdoch Children's Research Institute, Parkville, Victoria, Australia
Otto-von-Guericke Universitaet, Universitaetskinderklinik, Magdeburg, Germany
Universitätsklinikum Münster, Münster, Germany
Osaka University Hospital, Osaka, Japan
Saitama Children's Medical Center, Saitama, Japan
Tokushima University Hospital, Tokushima, Japan
Institut Catala de Traumatologica I Medicina de l'Esport, Barcelona, Spain
Hospital Sant Joan de Deu, Barcelona, Spain
Hospital Universitario Virgen de la Victoria, Málaga, Spain
Acibadem University School of Medicine, Istanbul, Turkey (Türkiye)
Guy's and St. Thomas NHS Foundation Trust Evelina Children's Hospital, London, United Kingdom
Sheffield Children's NHS Foundation Trust, Sheffield, United Kingdom
Study leads
Medical Director, MD
Study Director
BioMarin Pharmaceutical